



DNA Vaccine Development and Delivery Methods: Current Status and Future Perspective

Guest Editor:

Dr. Muthu Narayanan

Masonic Medical Research
Institute, Utica, NY 13501, USA

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editor

Genetic vaccines use one or more of the genes of the virus to activate the host immune response. DNA vaccines instigate cell-mediated immunity, which is effective against many pathogens, compared to standard vaccines that fail to work. A pathogenic epitope is expressed in the host after DNA vaccination, which makes it more effective than the standard vaccine. Moreover, the antigenicity is altered in the manufacturing process of the live attenuated or killed vaccine, which is not observed in the DNA vaccines. The process of construction and manufacturing is very simple with DNA vaccines.

Vaccination for many communicable (including Covid-19) and non-communicable diseases (cancer, atherosclerosis) is still a distant dream in both developed and developing countries. This Special Issue will focus on DNA vaccine development and delivery methods for communicable and non-communicable diseases. Research articles, review articles, and short communication based on the current status and future perspectives of the DNA vaccination development are invited.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com